The analysis of QOL in the patients of GERD with chronic liver disease after the treatment of PPI or H2-B
Phase 4
- Conditions
- The patients of GERD with chronic liver disease
- Registration Number
- JPRN-UMIN000002941
- Lead Sponsor
- CHiba University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
The patients with allergy for sodium rabeprazole and ranitidine hydrochloride The patients with severe live failure The patients treated by Interferon or with malignant tumor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The symptons of upper gastrointestine evaluated by F-sacle
- Secondary Outcome Measures
Name Time Method The symptons by SF-8 gastrointesitinal peptide
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does chronic liver disease impact PPI and H2-B efficacy via CYP450 metabolism in GERD patients?
What is the comparative effectiveness of PPIs versus H2-Bs in improving QOL for GERD patients with cirrhosis or hepatitis?
Which biomarkers predict response to PPI or H2-B therapy in patients with both GERD and chronic liver disease?
What are the adverse event profiles of PPIs and H2-Bs in GERD patients with hepatic impairment, and how are they managed?
Are there adjunct therapies or alternative drugs to PPIs and H2-Bs for GERD management in patients with chronic liver disease?